阿比特龙联合泼尼松与恩扎卢胺对mCRPC患者报告结局的影响:AQUARiUS研究12个月最终分析
AQUARiUS是一项前瞻性12个月观察性研究,纳入丹麦、法国和英国的mCRPC患者,比较阿比特龙联合泼尼松(N=105)与恩扎卢胺(N=106)对患者报告结局的影响。结果显示,阿比特龙组在认知障碍和疲劳等关键PRO条目上显著优于恩扎卢胺组,且从治疗早期即出现差异,疲劳和乏力不良事件发生率更低。
要点
- 阿比特龙组在认知功能和疲劳多个PRO条目上显著优于恩扎卢胺组。
- 阿比特龙组发生认知和疲劳临床意义恶化的患者比例显著更少。
- 疲劳和乏力不良事件阿比特龙组低于恩扎卢胺组(5% vs 15%;10% vs 11%)。
核心结论
- 在真实世界环境中,12个月分析提示阿比特龙联合泼尼松相比恩扎卢胺在疲劳和认知功能方面具有优势,且该差异在治疗开始后早期即出现。
- 选择mCRPC治疗时应考虑这一差异。
研究设计与样本
- AQUARiUS(NCT02813408)为前瞻性、12个月观察性研究,纳入丹麦、法国和英国的mCRPC患者。
- 阿比特龙治疗组N=105,恩扎卢胺治疗组N=106,按常规实践治疗。
- 使用FACT-Cog、BFI-SF、BPI-SF和EORTC QLQ-C30在基线和常规访视时收集PRO。
- 采用重复测量线性模型和logistic模型分析,校正基线特征。
主要发现
- 关键PRO条目(认知障碍和疲劳)在研究期间显著(p<0.05)有利于阿比特龙相比恩扎卢胺。
- FACT-Cog的「感知认知障碍」和「他人评论」;BFI-SF的「当前疲劳」「通常疲劳水平」和「最严重疲劳水平」;QLQ-C30的「认知功能」和「疲劳」在至第12个月的连续三个或以上时期显著有利于阿比特龙。
- 从研究开始,接受阿比特龙的患者发生一次或以上认知和疲劳临床意义恶化(CMW) episode显著更少。
- 疲劳和乏力(不良事件)阿比特龙组低于恩扎卢胺组(5% vs 15% 和 10% vs 11%)。
- 无治疗相关死亡。
关键数值与推荐
- FACT-Cog、BFI-SF和QLQ-C30中认知与疲劳相关条目在连续三个或以上时期显著有利于阿比特龙(p<0.05)。
- 疲劳不良事件发生率阿比特龙组5% vs 恩扎卢胺组15%;乏力10% vs 11%。
临床怎么用
- 在mCRPC治疗选择中,可将疲劳和认知功能影响作为考量因素,阿比特龙联合泼尼松在真实世界中显示出早期且持续的疲劳和认知优势。
局限性
- 研究缺乏随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have examined patient-reported outcomes (PROs) with abiraterone acetate plus prednisone (abiraterone) versus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine the impact of abiraterone and enzalutamide on PROs. DESIGN, SETTING, AND PARTICIPANTS: AQUARiUS (NCT02813408) was a prospective, 12-mo, observational study in patients with mCRPC from Denmark, France, and the UK. INTERVENTION: Abiraterone or enzalutamide treatment according to routine practise. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were collected over 12 mo using Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Brief Fatigue Inventory-Short Form (BFI-SF), Brief Pain Inventory-Short Form, and European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (QLQ-C30) at baseline and routine visits. Outcomes included mean change in PROs, patients with clinically meaningful worsening (CMW) in PROs, and safety. Data were analysed using repeated measures linear and logistic models adjusted for baseline characteristics. RESULTS AND LIMITATIONS: Abiraterone-treated (N = 105) and enzalutamide-treated (N = 106) patients were included. Key PRO items (cognitive impairments and fatigue) were significantly (p < 0.05) in favour of abiraterone versus enzalutamide during the study. "Perceived cognitive impairment" and "comments from others" (FACT-Cog); "fatigue right now", "usual level of fatigue", and "worst level of fatigue" (BFI-SF); and "cognitive functioning" and "fatigue" (QLQ-C30) were significantly in favour of abiraterone over enzalutamide for three or more consecutive periods up to month 12. From study initiation, significantly fewer patients receiving abiraterone experienced one or more CMW episode in cognition and fatigue. Fatigue and asthenia (adverse events) were lower with abiraterone than with enzalutamide (5% vs 15% and 10% vs 11%, respectively). There were no treatment-related deaths. Limitations included lack of randomisation. CONCLUSIONS: In a real-world setting, this 12-mo analysis suggests an advantage of abiraterone acetate plus prednisone over enzalutamide on fatigue and cognitive function; this finding occurred early after treatment initiation. This difference should be considered when choosing treatment. PATIENT SUMMARY: This study looked at the effect of two treatments (abiraterone acetate plus prednisone and enzalutamide) for metastatic castration-resistant prostate cancer on patient quality of life over 12 mo. Using established questionnaires, patients reported that they experienced less fatigue and cognitive impairments (including memory loss and reduced thinking abilities) with abiraterone acetate plus prednisone than with enzalutamide.
引用
- Thiery-Vuillemin A, Poulsen MH, Lagneau E, et al. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study. Eur Urol. 2019. PMID: 31594705. doi:10.1016/j.eururo.2019.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。